⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Announces Proposed Public Offering
globenewswire.com
OTLK
OTLKW
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
globenewswire.com
OTLK
AXON
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
prnewswire.com
TEVA
OTLK
PFE
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
OTLKW